PAVmed (PAVM) Q2 2025 earnings summary

Executive summary

• Q2 2025 saw 2,756 EsoGuard tests processed, generating $1.2 million in revenue, with expanded insurance coverage including Highmark Blue Cross Blue Shield and new strategic partnerships such as Hoag Health.

• Completed $16.1 million public offering for Lucid and $2.5 million equity financing for Veris, strengthening balance sheets and extending cash runway into 2026.

• Veris relaunched development of its implantable physiological monitor and secured a strategic partnership with OSU - The James for commercial launch.

• Lucid Diagnostics deconsolidated as of September 10, 2024, now accounted for as an equity method investment.

• Substantial doubt exists about the ability to continue as a going concern due to recurring losses and negative cash flows, despite recent financings.

Financial highlights

• Q2 2025 revenue for EsoGuard was $1.2 million, with total revenue and management fee income at $3.16 million; operating expenses were $4.7 million.

• GAAP net loss attributable to common stockholders was $13.3 million, or $(0.74) per diluted share; non-GAAP adjusted loss was $1.8 million, or $(0.11) per share.

• Cash and cash equivalents stood at $4.0 million as of June 30, 2025, up from $1.2 million at year-end 2024.

• Operating loss for Q2 2025 was $4.7 million, improved from $13.7 million in Q2 2024.

• Working capital deficiency of $5.0 million at June 30, 2025, including $6.8 million in current convertible notes.

Outlook and guidance

• Lucid expects further commercial expansion with new insurance coverage, strategic partnerships, and is targeting Medicare coverage, with a key CAC meeting scheduled for September 4, 2025.

• Veris is advancing toward FDA clearance and commercial deployment of its implantable monitor.

• Company expects recurring losses and negative cash flows to persist; additional capital will be needed.

• PAVmed is evaluating new opportunities to leverage its shared services model and diversify its portfolio.